How lung autoantibodies and donor/recipient immune cells cause early lung transplant injury

Synergistic roles of lung autoantibodies, donor nonclassical monocytes and recipient classical monocytes in mediating primary graft dysfunction

NIH-funded research Northwestern University · NIH-11193899

This project looks at whether lung-specific autoantibodies together with donor and recipient immune cells drive the severe early lung injury that affects people after lung transplantation.

Quick facts

Grant typeP01 program project
Study typeNIH-funded research
Funding institutionNorthwestern University NIH-funded
Lab location1 site (Chicago, United States)
Project IDNIH-11193899 on NIH RePORTER

What this research studies

This project aims to explain why many people develop primary graft dysfunction (PGD) in the first days after a lung transplant. Researchers will analyze blood and lung samples from transplant patients for lung-restricted autoantibodies and immune cell types, and they will use mouse lung transplant models to reproduce and study the injury process. The team will follow donor nonclassical monocytes and recipient classical monocytes to see how they form immune complexes, activate complement, recruit neutrophils, and release enzymes that expose hidden self-antigens. By combining human sample analysis with controlled animal experiments, they plan to map the chain of events that leads to early graft failure.

Who could benefit from this research

Good fit: Ideal candidates are people preparing for or recently having undergone lung transplantation who could provide blood or lung samples or be monitored for lung-restricted autoantibodies.

Not a fit: People who have not had a lung transplant or who are unwilling to provide samples or follow-up are unlikely to receive direct benefit from this project.

Why it matters

Potential benefit: If successful, this work could identify ways to prevent or treat primary graft dysfunction after lung transplant, improving early survival and reducing long-term rejection.

How similar studies have performed: Previous clinical observations and mouse experiments have linked lung autoantibodies to worse transplant outcomes, though the combined roles of donor nonclassical and recipient classical monocytes are a newer, less-tested focus.

Where this research is happening

Chicago, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.